Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV) by 6.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,041 shares of the company’s stock after purchasing an additional 6,595 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Verve Therapeutics worth $557,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of VERV. Cornercap Investment Counsel Inc. boosted its holdings in shares of Verve Therapeutics by 13.5% in the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after buying an additional 1,778 shares during the period. Arizona State Retirement System lifted its position in shares of Verve Therapeutics by 14.1% in the 2nd quarter. Arizona State Retirement System now owns 16,386 shares of the company’s stock valued at $80,000 after acquiring an additional 2,019 shares in the last quarter. Accredited Investors Inc. boosted its stake in Verve Therapeutics by 14.3% in the 3rd quarter. Accredited Investors Inc. now owns 20,000 shares of the company’s stock worth $97,000 after purchasing an additional 2,500 shares during the period. FMR LLC grew its position in Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after purchasing an additional 3,873 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Verve Therapeutics by 20.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,105 shares of the company’s stock valued at $137,000 after purchasing an additional 4,759 shares during the period. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

Shares of NASDAQ VERV opened at $5.74 on Friday. Verve Therapeutics, Inc. has a one year low of $4.30 and a one year high of $19.34. The business’s 50-day moving average price is $5.78 and its two-hundred day moving average price is $5.66. The company has a market capitalization of $485.97 million, a P/E ratio of -2.33 and a beta of 1.71.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The firm had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm’s revenue was up 120.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.72) earnings per share. On average, equities analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VERV. Royal Bank of Canada lowered their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. HC Wainwright lowered their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.